Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc. (COLL)
Filing Type: Form 8-K (Current Report)
Date of Report: February 27, 2025
Reporting Period: The filing announces financial results for the quarterly period and fiscal year ended December 31, 2024. The full text of the press release and earnings presentation are attached as exhibits but are not included in the body of this 8-K.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1) and earnings presentation (Exhibit 99.2), which are furnished but not filed within this document.
Material Changes and Corporate Events
- Executive Departure: Shirley Kuhlmann, Executive Vice President, Chief Administrative Officer, General Counsel, and Secretary, will step down effective March 7, 2025.
- Termination Terms: Ms. Kuhlmann's departure is classified as a termination without cause pursuant to her existing employment agreement.
- Financial Announcement: The Company released its Q4 and full-year 2024 financial results on the date of this filing.
Guidance, Outlook, and Risks
The filing text does not provide specific details regarding future guidance, management commentary, risks, or contingencies. These items are contained within the attached earnings presentation (Exhibit 99.2) and press release (Exhibit 99.1).
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2024 financial results, including revenue, net loss, and cash position.
- Examine Exhibit 99.2 (Earnings Presentation) for updated business outlook, product pipeline status, and forward-looking guidance.
- Verify the terms of the separation agreement for Shirley Kuhlmann to understand potential severance costs or legal implications.
- Confirm the appointment of interim or permanent replacements for the roles of Chief Administrative Officer, General Counsel, and Secretary.